Key Points
- PMI submitted evidence at the FDA’s Tobacco Products Scientific Advisory Committee (TPSAC) meeting to support ZYN’s application for a modified risk tobacco product (MRTP) designation, enabling communications to U.S. adult smokers aged 21 and over that fully switching may reduce certain smoking-related risks.
- The proposed MRTP claim covers risk reductions for six diseases; PMI cited FDA meeting materials saying the claim is “scientifically accurate.”
- Key evidence includes that ZYN contains substantially lower levels of harmful chemicals than cigarettes and was assessed for its ability to help smokers switch completely.
- PMI also emphasized the need to limit impacts on youth and other non-target groups.
- ZYN received FDA marketing authorization via the PMTA pathway in January 2025; the MRTP application covers multiple flavors and 3 mg/6 mg nicotine strengths.
2Firsts, January 26, 2026
According to Business Wire, Philip Morris International (PMI) said its expert team presented scientific evidence at the U.S. Food and Drug Administration’s (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) meeting, urging the committee to recommend that the FDA grant ZYN nicotine pouches a modified risk tobacco product (MRTP) designation.
If approved, the designation would allow PMI to communicate to adult smokers of legal age (21 and over) in the United States that switching completely to ZYN could reduce the risk of multiple smoking-related diseases.
PMI said the all-day meeting, held on January 22 local time, was part of the FDA’s review of an MRTP application submitted by PMI affiliate Swedish Match USA Inc. The application proposes the following reduced-risk statement: “Switching completely from cigarettes to ZYN reduces the risk of oral cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.” In its release, PMI cited FDA meeting materials stating that “the evidence demonstrates that the proposed modified risk claim is scientifically accurate.”
PMI added that data presented at the meeting indicated the proposed statement could improve audience understanding that switching from cigarettes to ZYN may reduce the six health risks listed, while consumers can also recognize that ZYN is not risk-free but poses a significantly lower risk than continuing to smoke.
The company said the evidence reviewed by the committee included findings that ZYN contains substantially lower levels of harmful chemicals than cigarettes, and data evaluating its performance in helping smokers achieve a “complete switch.” It also stressed that impacts on youth and other non-target populations should be kept low.
On regulatory progress, PMI said ZYN received FDA marketing authorization via the premarket tobacco product application (PMTA) pathway in January 2025. The MRTP submission covers the same portfolio of PMTA-authorized ZYN products, including flavors such as Cool Mint, Peppermint, Spearmint, Wintergreen, Citrus, Coffee, Cinnamon, Smooth, Chill and Menthol, and includes nicotine strengths of 3 mg and 6 mg.
Cover image source: PMI website.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
